Fig. 7
From: Hypertonicity-enforced BCL-2 addiction unleashes the cytotoxic potential of death receptors
Hypertonicity enhances TRAIL responsiveness of patient-derived melanoma cells. a–c ICNI-5li (derived from patient 1), ARST-1 (derived from patient 2), and AXBI (derived from patient 3) cells were treated with the indicated concentrations of KillerTRAIL in the presence and absence of NaCl (50, 75, and 100 mM, respectively). d AXBI cells (derived from patient 3) were treated with the indicated concentrations of conatumumab (cross-linked with 1 µg/ml protein G). e ARST-1 and AXBI cells (derived from patients 2 and 3) cells were challenged with either soluble trimeric FLAG-TRAIL or oligomerized FLAG-TRAIL (through incubation with 1 µg/ml anti-FLAG antibody) in the presence and absence of the indicated concentrations of NaCl. Shown are data points and mean ± SEM from three independent experiments
